Pyxis Oncology, Inc. Cash Flow Statement
PYXS|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$58M
FY2025
Free Cash Flow
-$58M
FY2025
Capital Expenditures
$237,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Pyxis Oncology, Inc. used $58M in operating cash flow and negative free cash flow of $58M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$77.3M | -$73.8M |
| Depreciation & Amortization | $3.0M | $1.9M |
| Operating Cash Flow | -$57.7M | -$70.7M |
| Capital Expenditures | $237.0K | $6.7M |
| Free Cash Flow | -$57.9M | -$77.4M |
| FCF Margin | -358.7% | -479.6% |